维普期刊资源整合服务平台（V6.5）

107篇 您的检索式：作者名="Loupakis F"

选中清除导出查看参考文献查看引证文献引用追踪共6页首页上一页第1页下一页末页 /6 跳转

	题名	作者	年代	出处	被引量
1	Pharma- cogenetic profiling' in patients with advanced color- ectal cancer treated with first-line FOLFOX-4 chem- otherapy显示文摘	Ruzzo A Graziano F Loupakis F	2007	J ClinOncol2007，25，10：	1
2	Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer显示文摘	Graziano F Ruzzo A Loupakis F	2008	J Clin Oncol2008，26，9：	1
3	Palliative treatment of unresectable metastatic colorectal cancer显示文摘	Fornaro L Masi G Loupakis F		0，，01：	1
4	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer:updated overall survival and molecular subgroup analyses of the open-label,phase 3 TRIBE study 显示文摘	Cremolini C Loupakis F Antoniotti C	2015	Lancet Oncol2015，16，13：	1
5	Caveolin-1 is a novel regulator of K-RAS-dependent migration in colon carcinogenesis显示文摘	Basu Roy UK Henkhaus RS Loupakis F	2013	Int J Cancer2013，133，1：	1
6	Primary tumor lo- cation as a prognostic factor in metastatic colorectal cancer显示文摘	Loupakis F Yang D Yau L	2015	J Natl Cancer Inst2015，107，3：	1
7	Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab显示文摘	Loupakis F Cremolini C Yang D	2013	PLo S One2013，8，66：	1
8	Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primary tumors as predictors of activity of cetuximab plus irinotecan treatment 显示文摘	Loupakis F Pollina L Stasi I	2008	J Clin Oncol2008，，：	1
9	PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for pa- tients with metastatic colorectal cancer显示文摘	Loupakis F Pollina L Stasi I	2009	J Clin Oncol2009，27，16：	1
10	PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer显示文摘	LOUPAKIS F POLLINA L STASI I	2009	J Clin Oncol2009，27，16：	1
11	High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice 显示文摘	Santini D Loupakis F Vincenzi B	2008	Oncologist2008，13，：	1
12	Liquid biopsy:monitoring cancer-genetics in the blood显示文摘	Crowley E Di Nicolantonio F Loupakis F	2013	Nat Rev Clin Oncol2013，10，8：	1
13	KRAS codon61,146 and BRAF mutations predict resistance to cetu-ximab plus irinotecan in KRAS codon 12 and 13 wild-typemetastatic colorectal cancer显示文摘	Loupakis F Ruzzo A Cremolini C	2009	Br J Cancer2009，101，4：	1
14	Liquid biopsy: monitoring cancer-genetics in the blood 显示文摘	Crowley E Di Nicolantonio F Loupakis F	2013	Nat Rev Clin Oncol2013，10，8：	1
15	First-line 5- fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer 显示文摘	Masi G Marcucci L Loupakis F	2006	Ann Oncol2006，17，：	1
16	Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primary tumors as predictors of activity of cetuximab plus irinotecan treatment 显示文摘	Loupakis F Pollina L Stasi I et at	2008	J Clin Oncol2008，26，：	1
17	Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-llne treatment of metastatic colorectal cancer 显示文摘	Masi G Vasile E Loupakis F	2008	Clin Colorectal Cancer2008，7，：	1
18	Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy显示文摘	Ruzzo A Graziano F Loupakis F	2007	J Clin Oncol2007，25，10：	1
19	Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy显示文摘	Ruzzo A Graziano F Loupakis F	2007	Clin Oncol2007，25，10：	1
20	Pharmacogenetic profiling in patients with advanced colorectal cancer treated with firstline FOLFOX-4 chemotherapy 显示文摘	Ruzzo A Graziano F Loupakis F	2007	J Clin Oncol2007，25，10：	1

返回顶部每页显示：

共6页首页上一页第1页下一页末页 /6 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示